Additionally, TELO2, ZMYND19, miR-143, miR-378a, cg00687383 (MED4), and cg02318866 (JMJD6; METTL23) were identified as highly associated with the recurrence-risk of PRAD patients. This evidence concerns the gene JMJD6 and prostate adenocarcinoma.